Works matching IS 10538569 AND DT 2021 AND VI 30 AND IP 3

Results: 17

Measured and accounted‐for confounding in pharmacoepidemiologic studies: Some thoughts for practitioners.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 277, doi. 10.1002/pds.5189
By:
- Roy, Jason;
- Mitra, Nandita
Publication type:
Article
Postoperative inpatient utilization of opioid and opioid‐sparing analgesics in the United States hospitals, 2007–2017.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 390, doi. 10.1002/pds.5187
By:
- Bykov, Katsiaryna;
- Patorno, Elisabetta;
- Franklin, Jessica M.;
- Vine, Seanna M.;
- Bateman, Brian T.
Publication type:
Article
Confirming diagnoses of acute pancreatitis with commonly available electronic data.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 313, doi. 10.1002/pds.5185
By:
- Nichols, Gregory A.;
- Déruaz‐Luyet, Anouk;
- Iliev, Hristo;
- Brodovicz, Kimberly G.
Publication type:
Article
Ways COVID‐19 may impact unrelated pharmacoepidemiologic research using routinely collected data.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 400, doi. 10.1002/pds.5182
By:
- Webster‐Clark, Michael
Publication type:
Article
Initial opioid prescription patterns and the risk of ongoing use and adverse outcomes.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 379, doi. 10.1002/pds.5180
By:
- Gomes, Tara;
- Campbell, Tonya;
- Tadrous, Mina;
- Mamdani, Muhammad M.;
- Paterson, J. Michael;
- Juurlink, David N.
Publication type:
Article
Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 350, doi. 10.1002/pds.5174
By:
- Segec, Andrej;
- Slattery, Jim;
- Morales, Daniel R.;
- Januskiene, Justina;
- Kurz, Xavier;
- Arlett, Peter
Publication type:
Article
Effectiveness of risk minimisation measures for valproate: A drug utilisation study in Europe.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 292, doi. 10.1002/pds.5166
By:
- Toussi, Massoud;
- Shlaen, Margarita;
- Coste, Florence;
- Voogd, Hanka;
- Dimos, Vasilis;
- Kaplan, Sigal
Publication type:
Article
Monitoring real‐life utilization of pembrolizumab in advanced melanoma using the Portuguese National Cancer Registry.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 342, doi. 10.1002/pds.5163
By:
- Borges, Fábio C.;
- Ramos, Catarina;
- Ramos, Adriana;
- Mendes, Gonçalo P.;
- Murteira, Rodrigo;
- Soares, Patrícia;
- Furtado, Claudia;
- Miranda, Ana C.;
- Costa, Filipa A.
Publication type:
Article
What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 334, doi. 10.1002/pds.5162
By:
- Januskiene, Justina;
- Segec, Andrej;
- Slattery, Jim;
- Genov, Georgy;
- Plueschke, Kelly;
- Kurz, Xavier;
- Arlett, Peter
Publication type:
Article
Empirical assessment of case‐based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (SNDS).
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 320, doi. 10.1002/pds.5161
By:
- Thurin, Nicolas H.;
- Lassalle, Régis;
- Schuemie, Martijn;
- Pénichon, Marine;
- Gagne, Joshua J.;
- Rassen, Jeremy A.;
- Benichou, Jacques;
- Weill, Alain;
- Blin, Patrick;
- Moore, Nicholas;
- Droz‐Perroteau, Cécile
Publication type:
Article
New prescription of antihyperglycemic agents among patients with diabetes in Germany: Moderate concordance between health insurance data and self‐reports.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 304, doi. 10.1002/pds.5160
By:
- Brüne, Manuela;
- Andrich, Silke;
- Haastert, Burkhard;
- Kaltheuner, Matthias;
- Icks, Andrea
Publication type:
Article
Effectiveness of risk minimisation measures for valproate: A cross‐sectional survey among physicians in Europe.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 283, doi. 10.1002/pds.5119
By:
- Toussi, Massoud;
- Isabelle, Bardoulat;
- Tcherny‐Lessenot, Stephanie;
- Voogd, Hanka;
- Dimos, Vasilis;
- Kaplan, Sigal
Publication type:
Article
Drug utilization study on immediate release Fentanyl in Spain. Prevalence, incidence, and indication.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 371, doi. 10.1002/pds.5118
By:
- González‐Bermejo, Diana;
- Rayón‐Iglesias, Pilar;
- Rodríguez‐Pascual, Alfonso;
- Álvarez‐Gutiérrez, Arturo;
- Fernández‐Dueñas, Ana;
- Montero‐Corominas, Dolores;
- Huerta‐Álvarez, Consuelo
Publication type:
Article
Identifying opioid dose reductions and discontinuation among patients with chronic opioid therapy.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 395, doi. 10.1002/pds.5096
By:
- Hallvik, Sara E.;
- Johnston, Kirbee;
- Geddes, Jonah;
- Leichtling, Gillian;
- Korthuis, P. Todd;
- Hartung, Daniel M.
Publication type:
Article
Patterns of opioid use in older people diagnosed with cancer in New South Wales, Australia.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 360, doi. 10.1002/pds.5081
By:
- Tervonen, Hanna E;
- Schaffer, Andrea L;
- Luckett, Tim;
- Phillips, Jane;
- Litchfield, Melisa;
- Todd, Adam;
- Pearson, Sallie‐Anne
Publication type:
Article
Issue Information.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 402, doi. 10.1002/pds.5044
Publication type:
Article
Issue Information.
Published in:
Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 3, p. 1, doi. 10.1002/pds.5314
Publication type:
Article